Carbotherapy-20 |
Carbotherapy-20 is classified as a Medicinal gas. It is used to induce vasodilation in the central nervous system. Carbotherapy-20 complies with the European Pharmacopoeia.
Composition: CO2: 20%; O2: QS Therapeutic Indication: Cerebral stimulation Product Availability: Spain | |
Carbotherapy-4.5 |
Carbotherapy-4.5 is classified as a Medicinal gas. It is used to induce vasodilation in the central nervous system. Carbotherapy-4.5 complies with the European Pharmacopoeia.
Composition: CO2: 20%; O2: QS Therapeutic Indication: Cerebral stimulation Product Availability: Spain | |
CEC-1 |
CEC-1 is classified as Medicinal gas. It is used to treat sudden deafness and to stimulate the central respiratory drive. CEC-1 complies with the European Pharmacopoeia.
Composition: CO2: 5%; Oxygen: QS Therapeutic Indication: Treatment of sudden deafness and to stimulate central respiratory drive. Product Availability: Belgium, Czech Republic, France, Netherlands
| |
CEC-2 |
CEC-2 is classified as Medicinal gas. It is used to treat sudden deafness and to stimulate the central respiratory drive. CEC-2 complies with the European Pharmacopoeia.
Composition: CO2: 7%; Oxygen: QS Therapeutic Indication: Treatment of sudden deafness and to stimulate the central respiratory drive. Product Availability: France | |
NOXAP®200 |
NOXAP 200 is a Medicinal gas. It is used for the treatment of Persistent Pulmonary Hypertension of the Newborn in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. The NOXAP 200 complies with the European Pharmacopeia.
Composition: NO 200 ppm; N2: QS Therapeutic Indication: Treatment of newborns to fend off 34 weeks of gestation, with hypoxemic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. Product Availability: Belgium, Czech Republic, France, Netherlands, Portugal, Spain, United Kingdom
| |
NOXAP®800 |
NOXAP 800 is a Medicinal gas. It is used for the treatment of Persistent Pulmonary Hypertension of the Newborn in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. The NOXAP 800 complies with the European Pharmacopeia.
Composition: NO 800 ppm; N2: QS Therapeutic Indication: Treatment of newborns to fend off 34 weeks of gestation, with hypoxemic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. Product Availability: Belgium, Czech Republic, France, Netherlands, Portugal, Spain, United Kingdom
| |
OXYNOX® |
OXYNOX® is a Medicinal gas. It is used as an analgesic agent for emergency medical assistance (trauma, burns, pain during transport), for painful procedures of short duration, for dental procedures and in obstetrics when epidural analgesia is contraindicated or not effective. OXYNOX complies with the European Pharmacopoeia.
Composition: Nitrous Oxide: 50% (mol/mol) and Oxygen: 50% (mol/mol) Therapeutic Indication: Analgesia for emergency medical assistance to patients with trauma, burns, pain in transport. Preparation of painful procedures of short duration in adults and children, including lumbar puncture, bone marrow, small superficial surgery, burn dressings, reduction of simple fractures, dislocations reduction of certain devices and venipuncture in children. Dental, hospital exclusively for children, anxious patients or disabled. In obstetrics when epidural analgesia is cons-indicated or only partially effective. Product Availability: France and United Kingdom | |
VENTILOX® |
VENTILOX is a Medicinal gas. It is used as an adjuvant therapy in acute severe asthma while the etiological treatment starts to take effect. The VENTILOX complies with the European Pharmacopeia.
Therapeutic Indication: The Venitilox is used as an adjuvant in acute respiratory distress obstructive origin in adults and children while the etiological treatment starts to take effect. Severe episodes of asthma in adults and children who respond poorly to conventional treatment. Product Availability: Belgium, Czech Republic, France, Germany, Netherlands, Portugal, Spain, United Kingdom | |